Investigation of pathways regulating early antiangiogenic response to bevacizumab given prior to neoadjuvant breast cancer chemotherapy.

Trial Profile

Investigation of pathways regulating early antiangiogenic response to bevacizumab given prior to neoadjuvant breast cancer chemotherapy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2010

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 08 Jun 2010 Thrity-one patients have been recruited to date, according to information reported at ASCO 2010.
    • 08 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top